These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6681397)

  • 1. Dose selection as it pertains to testing a prodrug in carcinogenicity bioassays.
    Szczech GM; Tucker WE
    Toxicol Pathol; 1983; 11(1):55-9. PubMed ID: 6681397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
    Osimitz TG; Droege W; Boobis AR; Lake BG
    Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of carcinogenicity studies, dose selection, route, blood levels, transformation.
    Neal RA
    Toxicol Pathol; 1983; 11(1):48-54. PubMed ID: 6681396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays.
    Paini A; Scholz G; Marin-Kuan M; Schilter B; O'Brien J; van Bladeren PJ; Rietjens IM
    Mutagenesis; 2011 Sep; 26(5):605-18. PubMed ID: 21642616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinogenicity testing of eliglustat in mice and rats.
    Dagher R; Watzinger M; Chevalier G; Thirion-Delalande C; Gervais F; Forster R
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):401-12. PubMed ID: 26232705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic toxicity and carcinogenicity guidelines.
    Page NP
    J Environ Pathol Toxicol; 1977; 1(2):161-82. PubMed ID: 553129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies).
    National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services
    Natl Toxicol Program Tech Rep Ser; 2002 May; (504):1-357. PubMed ID: 12087420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of carcinogenicity from two versus four sex-species groups in the carcinogenic potency database.
    Gold LS; Slone TH
    J Toxicol Environ Health; 1993 May; 39(1):143-57. PubMed ID: 8492327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
    Floyd E; Mann P; Long G; Ochoa R
    Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological and experimental applications to occupational cancer prevention.
    Vainio H; Hemminki K
    J UOEH; 1989 Mar; 11 Suppl():323-45. PubMed ID: 2664947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicology and carcinogenesis studies of pyrogallol (CAS No. 87-66-1) in F344/N rats and B6C3F1/N mice (dermal studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2013 Feb; (574):1-167. PubMed ID: 23518671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of non-mammalian species in bioassays for carcinogenicity.
    Bunton TE
    IARC Sci Publ; 1999; (146):151-84. PubMed ID: 10353387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consideration of non-linear, non-threshold and threshold approaches for assessing the carcinogenicity of oral exposure to hexavalent chromium.
    Haney J
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):834-52. PubMed ID: 26493004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
    Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
    J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.